Partnership celebrates the Blue Jackets’ 25th season and their longstanding commitment to literacy, education, and community ...

Phyrago is a novel formulation of Sprycel ® (dasatinib) designed to enable concomitant use with proton pump inhibitors (PPIs) and H 2 receptor antagonists (H 2 RAs). 1 Clinical data showed no ...

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...

A Charlotte-based library services company will close its doors next year. Baker & Taylor will shutter its headquarters off ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...